Regenics AS is a Norwegian biotechnology company focused on developing innovative wound care technologies utilizing marine ingredients sourced from the coast of Norway. The company’s product pipeline includes advanced wound care solutions such as Collex®, a 3D printed dressing that incorporates HTX™, a bioactive substance derived from unfertilized salmon roe. This product is designed to facilitate the healing of partial thickness burns and chronic wounds and is currently in pre-clinical development. Another product, Vernex®, is a hydrogel wound spray also based on HTX™, aimed at treating similar wound types. Both products reflect Regenics' commitment to sustainability by reducing waste in the aquaculture industry while leveraging the unique healing properties of marine-derived ingredients.

In addition to Collex® and Vernex®, Regenics AS is developing WoundClear™, a novel investigational drug derived from trout LCE, intended for enzymatic wound debridement. This product is still in the discovery stage. The company emphasizes the importance of sustainability in its operations and product development, aiming to redefine standards of care in wound management through the use of natural, bioactive substances. With a focus on addressing various wound types, including diabetic and chronic wounds, Regenics AS is positioned to make significant contributions to the field of wound care.

Norway

Regenics AS is a private Norwegian biotechnology company based in Oslo. Regenics develops novel wound care technologies, based on sustainable marine sources.

Regenics AS

Company Details